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Abstract 
Background: Human myeloid-derived suppressor cells (MDSC) have been described as a group of immature 
myeloid cells which exert immunosuppressive action by inhibiting function of T lymphocytes. While there is a huge 
scientific interest to study these cells in multiple human diseases, the methodological approach varies substantially 
between published studies. This is problematic as human MDSC seem to be a sensible cell type concerning not 
only cryopreservation but also time point after blood draw. To date data on delayed blood processing influencing 
cell numbers and phenotype is missing. We therefore evaluated the kinetics of granulocytic MDSC (gMDSC) and 
monocytic MDSC (mMDSC) frequencies after blood draw in order to determine the best time point for analysis of this 
recently defined cell type.
Methods: In this study, we isolated peripheral blood mononuclear cells (PBMC) of patients with HIV infection or solid 
tumors directly after blood draw. We then analyzed the frequencies of gMDSC and mMDSC 2, 4 and 6 h after blood 
draw and after an overnight rest by FACS analysis using the standard phenotypic markers. In addition, part of the cells 
was frozen directly after PBMC preparation and was measured after thawing.
Results: gMDSC levels showed no significant difference using fresh PBMC over time with a limitation for the 
overnight sample. However they were massively diminished after freezing (p = 0.0001 for all subjects). In contrast, 
frequencies of fresh mMDSC varied over time with no difference between time point 2 and 4 h but a significantly 
reduction after 6 h and overnight rest (p = 0.0005 and p = 0.005 respectively). Freezing of PBMC decreased the yield 
of mMDSC reaching statistical significance (p = 0.04). For both MDSC subgroups, FACS analysis became more difficult 
over time due to less sharp divisions between populations.
Conclusions: According to our data human MDSC need to be studied on fresh PBMC. gMDSC can be studied with 
delay, mMDSC however should be studied no later than 4 h after blood draw. These results are crucial as an increas-
ing number of clinical trials aim at analyzing MDSC nowadays and the logistics of blood processing implies delayed 
sample processing in some cases.
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Background
In the last decades newly described suppressors of 
the cellular immune system have become increasingly 
important: myeloid derived suppressor cells (MDSC). 
These cells are part of a group of immature cells with 
myeloid origin which act immunosuppressively by inhib-
iting function of T lymphocytes among others [1]. Firstly 
discovered in mice, MDSC have been shown in various 
studies in patients with solid tumors [2] like hepatocel-
lular carcinoma (HCC) [3], non-small cell lung cancer 
(NSCLC) [4], head and neck cancer [4], gastrointesti-
nal cancer [5] or melanoma [6, 7]. Recently MDSC were 
also found in peripheral blood of infectious diseases 
namely HIV [8] or tuberculosis [9]. All these studies on 
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approach. For this reason, translational studies on human 
MDSC are difficult to compare especially regarding two 
criteria: phenotypic markers and time point of analysis 
after blood draw.
MDSC can be divided in two main subgroups: granulo-
cytic MDSC (gMDSC) and monocytic MDSC (mMDSC) 
[1]. The markers to characterize human MDSC are 
heterogeneous and a lot of different markers are used 
depending on tumor or infection [1, 2, 8]. In studies in 
infectious diseases (HIV, HCV), gMDSC were defined 
to lack the expression of CD14 but to express CD15/
CD33/CD11b [8, 10] whereas mMDSC were character-
ized as CD14+/CD11b+/HLA-DR−/low cells [8, 10, 11] or 
additionally CD33+ cells [12, 13]. Other marker combi-
nations are CD33high/CD66bhigh/IL-4Rαinter/HLADRdim 
for Pseudomonas aeruginosa infection in cystic fibro-
sis [14] or LIN−/low/HLA-DR−/low/CD33+/CD11b+ for 
tuberculosis [9]. Previously mentioned studies in cancer 
characterized gMDSC as CD33+/HLA-DR−/CD66b+ [4] 
and mMDSC as CD14+ and HLA-DR−/low [3, 5–7]. The 
usage of a lineage cocktail [9, 15] is less frequent in recent 
studies. Dumitru et al. postulated a marker combination 
of CD11b/CD14/CD66b/CD33/HLA-DR/CD16 for iden-
tification of gMDSC and mMDSC within one peripheral 
blood mononuclear cells (PBMC) sample [2]. In conclu-
sion, to date the most established markers for gMDSC 
are CD14−, CD33+, CD66b+/CD15+ and CD11b+ and 
for mMDSC CD33+, CD14+ and HLA-DR−/low.
Other reasons which complicates the comparison of 
studies are the cryopreservation or kinetics of MDSC fre-
quencies after blood draw which seem to have an immense 
influence on the results. So far, there is data on the effect 
of cryopreservation of MDSC. Trellakis et  al., Kotsakis 
et al. and Duffy et al. [5, 15, 16] showed that freezing/thaw-
ing procedures of PBMC had influence on frequencies of 
MDSC and also on their function [15]. However, Trellakis 
et al. studied mainly gMDSC. Kotsakis et al. used pheno-
typic markers that are disparate to the markers used today 
as mentioned above rendering the data not transferrable 
to MDSC subsets used today. In spite of the existing data, 
many studies still use frozen PBMC to evaluate MDSC fre-
quencies. Therefore the harmful effects of cryopreserva-
tion on MDSC cannot be stressed enough.
Besides the influence of freezing PBMC, data on the 
time point of PBMC processing after blood draw is miss-
ing. In clinical settings, several hours often pass until 
the study subjects’ blood can be processed not only for 
observational studies but also in clinical trials. Looking 
at a sensible cell type, it is highly important to evaluate 
the rate of decay of these cells with increasing time after 
blood draw.
The aim of this study was to standardize the analytical 
process for assessing human MDSC. As critical aspects, 
we analyzed the time frame between blood draw and cell 
analysis and the recovery rate after freezing of gMDSC 
and mMDSC defined by standard phenotypic markers. 
Our results show that gMDSC can be used freshly after 
delayed processing with a reservation towards the over-
night rest. We confirm that they cannot be analyzed 
after cryopreservation. In contrast, we show that fresh 
mMDSC are significantly lost when rested for more than 
four hours after blood draw. However the recovery rate 
after freezing was better for this cell subtype.
Methods
Study subjects
42 individuals participated in the study after signing 
informed consent. The study was approved by the Insti-
tutional Review Board of the Ludwig-Maximilians-Uni-
versität, Munich, Germany.
The study subjects were divided into the follow-
ing groups: 25 patients with chronic viral infection 
[HIV-infected patients with no or less than 4  weeks 
of antiretroviral therapy (CD4 counts: median 165/
µl, range 1–891/µl; viral loads: median 37,350 copies/
ml, range  <50–3,365,672 copies/ml): 24; HCV-infected 
patient (Genotype 1b; viral load: 240,000 I.U./ml): 1], and 
17 subjects with advanced stage solid tumors before spe-
cific treatment (malignant melanoma: 9; non-small cell 
lung carcinoma (NSCLC): 6; hepatocellular carcinoma 
(HCC): 1; tracheal tumor: 1).
PBMC isolation, freezing and thawing
PBMC were isolated from freshly obtained EDTA blood 
by Ficoll density gradient centrifugation (Biocoll Separa-
tion Solution, Biochrom, Germany). Sample processing 
was performed 2, 4, 6 h and 20–26 h (= overnight) after 
blood draw. Between time points starting at approxi-
mately 2 h after blood draw, PBMC were stored in RPMI 
1640 (10 ml; PAA, Austria or Biochrom, Germany) sup-
plemented with 10 % FCS (Biochrom, Berlin, Germany), 
1  % penicillin–streptomycin (Biochrom, Germany), 
1 % L-Glutamin (PAA, Austria) and 1 % Hepes (Sigma-
Aldrich, Germany) at 37 °C and 5.0 % CO2. Samples were 
not stored as whole blood sample.
For freezing, PBMC (2 h after blood draw and directly 
after PBMC preparation) and freezing medium [90  % 
fecal calf serum (FCS) +  10 % DMSO] were pre-chilled 
on ice [16]. PBMC were resuspended in 1  ml freezing 
medium. The cryovial was transferred into a pre-chilled 
Nalgene™ Cryo 1  °C freezing container (cooling rate 
−1  °C/min; Nalgene®, USA) and stored at −80  °C over-
night. For long-term storage, vials were transferred into a 
liquid nitrogen storage container the next day.
PBMC were thawed by warming up frozen vials at 
37 °C in a water bath. PBMC were then transferred into 
Page 3 of 7Grützner et al. J Transl Med  (2016) 14:2 
supplemented RPMI 1640 (as described above) which 
was pre-chilled on ice and washed twice in media. The 
viability of cells was determined by trypan blue dye exclu-
sion method and was more than 88 %. Cells were used for 
assays immediately after thawing.
Flow cytometric analysis
Extracellular staining with fluorescent antibodies on 
fresh or frozen PBMC was done as described previously 
[8]. At each time point, analyses were performed for 
gMDSC and mMDSC respectively. The following anti-
bodies were used: gMDSC: CD11b-FITC, CD14-APC, 
CD15-PerCP, CD66b-PE [14, 17]; mMDSC: CD11b-
FITC, CD14-APC, CD33-PE, HLA-DR-PerCP, PerCP 
isotype control (all BioLegend, USA). Cells were ana-
lyzed on a FACSCalibur (BD, Germany) and analysis 
of data was done using FlowJo software 7.2.1 (TreeS-
tar, Inc. Ashland, OR). Gating strategies were accord-
ing to Vollbrecht et al. [8] and Rieber et al. [14, 17] for 
gMDSC. For the gating of mMDSC, we used a PerCP 
isotype control in order to gate for HLA-DR and our 
gating strategy was according to Dumitru et al. [2] (see 
Additional file 1: Figure S1). For the statistics, we indi-
cated MDSC as percentage of PBMC in all subgroups 
because the numbers of monocytes vary substantially 
in subjects with e.g. chronic viral infections. How-
ever, in the dot plots shown in Fig.  2, frequencies of 
the described populations are shown in percentages of 
monocytes.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
version 5.0. Differences between groups were determined 
by Mann–Whitney test. A p value of  <0.05 was consid-
ered to be statistically significant.
Results
No significant difference in frequencies of gMDSC 
after delayed sample processing, but significant reduction 
of mMDSC frequencies after 6 h and overnight rest
In comparison to T lymphocytes which can be frozen 
or cultured over weeks without altering their phenotype 
[18–23], MDSC are a rather sensible cell type. In order 
to determine the best time point for MDSC analysis 
after blood draw, we first studied the kinetics of gMDSC 
frequencies. Frequencies of CD11b+/CD14−/CD15+/
CD66b+ gMDSC after 2 h compared to 4, 6 h and even 
after an overnight rest were not significantly different in 
24 patients with chronic viral infections (p > 0.5) (Fig. 1a). 
After cryopreservation, the frequencies of gMDSC 
dropped to under 0.4  % in 22 of the patients, indepen-
dently of the frequencies at 2 h, and were reduced by 92 % 
on average. The loss of gMDSC numbers after freezing/
thawing was statistically highly significant (p = 0.0001).
For mMDSC, we used only three patients with HIV 
infection because mMDSC levels in the other patients 
with chronic viral infections were too low. In addition 
we recruited 17 study subjects with advanced stages of 
solid tumors (for entities see “Methods” section) who 
Fig. 1 Kinetics of gMDSC and mMDSC levels. Frequency of gMDSC (a) and mMDSC (b) within PBMC after 2, 4, 6 h, overnight rest (ON) and freezing/
thawing procedure (defrost). PBMC were stored in RPMI media after the ficoll separation. gMDSC were analysed in 24 patients with chronic viral 
infections and mMDSC in 17 patients with solid tumors and three HIV infected patients. There was no statistical significant difference in gMDSC 
frequencies over time (2, 4, 6 h, ON). Statistical significant reduction of gMDSC frequencies after freezing/thawing procedure (p = 0.0001; Mann–
Whitney test). The difference in frequencies in mMDSC is not significant after 4 h whereas their numbers were significantly reduced after a 6 h and 
overnight rest (p = 0.0005 and p = 0.005, respectively; Mann–Whitney test). mMDSC were more stable towards freezing/thawing, however the 
difference reached statistical significance (p = 0.039; Mann–Whitney test)
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exhibited high mMDSC frequencies. Overall, we found 
comparable CD33+/CD14+/HLA-DR−/low mMDSC fre-
quencies after 2 and 4  h in the 20 individuals studied. 
However, we observed a remarkable drop in frequencies 
after 6  h and overnight rest by 75 and 47  % which was 
statistically highly significant (p = 0.0005 and p = 0.005, 
respectively). Compared to gMDSC, mMDSC were not 
as sensitive to the freezing/thawing procedure. For the 
defrost sample, the overall reduction averaged 30  %. 
Compared to 2  h, in 5 subjects the rates of mMDSC 
were even higher (Figs.  1b, 2e) and in 3 subjects they 
were almost equal (reduction less than 15 %). None the 
less, the difference between the 2  h time point and the 
freezing/thawing sample reached statistical significance 
(p = 0.04, Fig. 1b).
In conclusion, gMDSC can be processed with delay 
without changing the result significantly whereas 
mMDSC are sensitive to resting for hours and PBMC 
should be processed within 4  h after blood draw for 
mMDSC analysis. Our results confirm that gMDSC can-
not be studied from frozen PBMC. mMDSC are less sen-
sitive to freezing. According to our data, they should still 
not be studied in frozen samples.
Alterations in MDSC phenotype over time
In the next step, we compared the dot blots of the various 
time points of gated MDSC as a shifting of the popula-
tions had been clearly visible on first inspection.
Based on the statistics, gMDSC can even be measured 
after an overnight rest. However comparison of the dot 
blots showed that the populations get more blurred over 
time (Fig. 2a–c). Especially in the overnight sample, the 
marker CD11b cannot be discriminated into positive 
and negative cells any more. This led to much higher 
numbers of gMDSC in a minority of samples (see Fig. 2b 
overnight time point). In addition we observed 5 indi-
viduals in whom gMDSC frequencies were substantially 
reduced after the 2  h time point (Fig.  2c). Figure  2a–c 
also shows well the loss of gMDSC after freezing/thaw-
ing. Dot blots of the CD66b+ and CD15+ population dif-
fered less after short term storage (see Additional file 2: 
Figure S2).
In analogy, we assessed the dot blots of mMDSC com-
paring the different time points. The most striking phe-
nomenon was that the marker HLA-DR stretched to 
higher values over time (Fig. 2d–f). This necessitated an 
adjustment of the gating cut-off between HLA-DRhigh 
and HLA-DRlow. We gated HLA-DR using an isotype 
control because this marker does not separate in two 
distinct populations (i.e. HLA-DR positive and HLA-
DR negative). A shifting of this population renders the 
marker—which is difficult to gate to begin with—even 
more challenging to gate.
As the PBMC were frozen directly after the ficoll sepa-
ration (2 h time point), the dot blots of mMDSC of the 
freezing/thawing time point resembled those of the 2  h 
time point with regard to HLA-DR (Fig.  2d–f). In the 
overnight sample the cell populations again got blurred 
with respect to CD33 (Fig. 2d–f). CD14 was the most sta-
ble marker in this setting (data not shown). Interestingly, 
there were also 5 samples where mMDSC were almost 
lost (reduction more than 70 % in comparison to 2 h time 
point) after freezing/thawing (Fig. 2f ).
These observations raise the reservation about resting 
PBMC overnight for gMDSC analysis and they under-
score the conclusion that mMDSC should not be ana-
lyzed later than 4 h after blood draw.
Discussion
Currently it is rarely feasible to compare the results 
of studies on human MDSC due to strongly differing 
approaches with regard to the preparation of the cells for 
analysis. Detailed information on time between blood 
draw and analysis of cells or their cryopreservation is 
often not provided in the respective publications [8, 13, 
15, 24]. The knowledge of the influence of these variables 
on the cells is poor to date. In this study we analyzed a 
critical aspect in MDSC research, namely the impact of 
short time storage of PBMC before analyses of MDSC 
which, to our knowledge, has not been investigated to 
date. Our results show that gMDSC tolerate storage up 
to 26 h at 37 °C and 5.0 % CO2 with limitations, but are 
not viable after freezing. mMDSC however should not 
be stored for more than 4 h after blood draw. Freezing is 
better tolerated by mMDSC.
It has been shown that granulocytes in peripheral 
blood are sufficiently viable for up to 22–26 h after blood 
draw, however they do change their density over time 
[25]. gMDSC are closely related to granulocytes [2] and 
their resistance towards delayed analysis is compara-
ble to granulocytes [25]. In addition, we also observed 
a markedly changing phenotype of gMDSC after over-
night rest, especially as far as CD11b was concerned, less 
pronounced for CD14. It has even been shown that the 
change in density of granulocytes leads to a significant 
increase of contaminating granulocytes within PBMC 
when the ficoll separation is done after 22–26 h [25]. We 
can exclude this contamination in our experiments as 
the ficoll separation of the blood samples was done right 
after blood draw and only PBMC in RPMI were used for 
storage.
Time points later than 4 h after blood draw showed 
significant reductions in mMDSC frequencies. We 
assume this is due to the adhesion of the monocytic 
cells to the vial surface. Under physiological conditions 
monocytes which are related to mMDSC circulate in 
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Fig. 2 Dot blot kinetics of MDSC. Representative dot plots of gMDSC (a–c) and mMDSC (d–f) after 2, 4, 6 h, overnight rest and freezing/thawing 
procedure of three HIV patients (gMDSC) and three patients with solid tumors (mMDSC). PBMC were stored in RPMI media after the ficoll separa-
tion gMDSC gated on CD11b+ and CD14− population (oval gate); for CD15+/CD66b+ gating see Additional file 2: Figure S2; mMDSC gated on 
CD33+ and HLA-DRlow/− (rectangle gate); CD14+ gating not shown. The majority of dot blots (a) of the CD11b+/CD14− population remained similar 
after 2, 4 and 6 h. However, it was not clearly definable after ON and almost disappeared after the freezing/thawing procedure. Divergent minor 
presentations were seen and are presented in the remaining panels: increasing gMDSC frequencies after overnight rest and relatively high gMDSC 
levels after freezing/thawing (b) as well as reduction of gMDSC numbers at 4, 6 h and overnight rest compared to the 2 h time point (c). Looking at 
mMDSC (CD33+ and HLADR−/low population), again the majority of dot blots presented as shown in 2d: similar numbers of mMDSC after 2 and 4 h 
and a clear reduction in mMDSC frequencies after 6 h. Populations are not well discriminable after overnight rest and after freezing/thawing. Minor 
divergent presentations are shown in the remaining panels: very high mMDSC frequencies after freezing/thawing (e) as well as increased frequen-
cies after overnight rest and loss of mMDSC after freezing/thawing (f)
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the bloodstream until they differentiate e.g. to mac-
rophages in inflamed tissue. Therefore monocytes 
have to adhere and migrate through the vascular 
endothelium [26, 27]. In vitro the ability of monocytes 
to adhere to glass surfaces was first described in 1966 
[28]. This adhesion was shown to be dependent on the 
surface material [29–32]. Interestingly, mMDSC fre-
quencies were lowest at the 6  h time point and again 
higher after overnight rest which was not statistically 
significant. We cannot explain this phenomenon at the 
moment. We can only speculate that the monocytic 
cells release their attachment to the vial surface after 
some time.
Our analyses also showed that resting of cells increased 
the gating difficulties for mMDSC as well. The marker 
HLA-DR is difficult to gate in general and we used an iso-
type control to overcome this problem. Short term stor-
age led to an additional blurring of the HLA-DR marker 
in the dot blots that was even challenging to overcome 
with the isotype control.
The data on freezing of gMDSC was impressive 
with an almost complete loss of the gMDSC popula-
tion after thawing. This seems natural as gMDSC are 
closely related to granulocytes and granulocytes do 
not tolerate freezing [33–35]. It is in line with data 
by Trellakis et al. who showed a reduction of gMDSC 
frequencies of more than 50  % in all tested samples 
after freezing [16]. Another study on freezing/thaw-
ing of MDSC used a lineage cocktail rendering the 
comparison of their data with ours difficult. However 
the population closest to our gMDSC, namely HLA-
DR−/LIN−/CD15+, also showed a 69  % reduction 
after freezing [15]. There is even less data on freez-
ing/thawing of mMDSC. In our hands, mMDSC were 
more resistant to the freezing procedure. However 
the difference between the 2 h time point and the fro-
zen sample still reached statistical significance. Pub-
lished data is conflicting in this point: while one study 
stated similar sensitivity towards freezing comparing 
mMDSC and gMDSC [16], two studies found no sig-
nificant difference between the frequency of fresh and 
frozen cells using the markers HLA-DR−/CD14+ for 
definition of cells. Duffy et al. even showed increased 
frequencies within frozen PBMC [5]. However, Kotsa-
kis et  al. reported abolished function of MDSC after 
freezing [15]. Consequently, based on our research 
and the literature, we cannot recommend using frozen 
samples for gMDSC or mMDSC analyses. If mMDSC 
have to be analyzed in frozen PBMC, ficoll separation 
and freezing should be done directly after blood draw 
as suggested by the results of the kinetics of mMDSC. 
In view of the reality of translational research with 
the clinical parts of studies being often conducted at 
different sites than the laboratory evaluation—some-
times even in different countries—this is unfortunate. 
However the data clearly shows that freezing of MDSC 
has to be avoided in order to accurately describe the 
situation in vivo.
Conclusions
MDSC are a very sensitive type of cells of the immune 
system in terms of time point of analysis. Their pre-
cise role in cancer and infectious diseases still remains 
an urgent target for future investigations which should 
be facilitated by harmonizing the analytical process. 
Our data show differences in sensitivity of gMDSC and 
mMDSC and are crucial for defining the ideal time point 
for analysis. For frozen/thawed gMDSC and mMDSC, we 
support the results from previous studies to analyse fresh 
PBMC. Of particular importance is our finding determin-
ing the first 4 h after blood draw as ideal time point for 
analyses of mMDSC but allowing processing of gMDSC 
within the same day.
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